Source: Eur Respir J 2006 Oct 01;28(4):799-807
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tamby M. C., Humbert M., Guilpain P., Servettaz A., Dupin N., Christner J. J., Simonneau G., Fermanian J., Weill B., Guillevin L., Mouthon L.. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006 Oct 01;28(4):799-807

Member's Comments

No comment yet.

Related content which might interest you: Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma Source: Eur Respir J 2012; 39: 1405-1414 Year: 2012 Anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 339s Year: 2006 Screening for pulmonary arterial hypertension in systemic sclerosis Source: Eur Respir Rev 2009; 18: 162-169 Year: 2009 Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 923-925 Year: 2010 Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Source: Eur Respir J 2009; 33: 371-379 Year: 2009 Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011 Pulmonary hypertension and arterial stiffness in patients with systemic scleroderma Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Pulmonary hypertension in systemic scleroderma Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy? Source: Eur Respir J 2010; 35: 223-224 Year: 2010 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Vasodilator testing in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Membrane diffusion and capillary blood volume in systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) and systemic sclerosis (SSc) without PAH Source: Eur Respir J 2007; 30: Suppl. 51, 342s Year: 2007 Charactaristics and prognosis of autoimmune antibody-positive patients of idiopathic pulmonary arterial hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA Source: ERJ Open Res, 6 (2) 00309-2019; 10.1183/23120541.00309-2019 Year: 2020